Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Nuvation Bio Inc.

35 indications, side-by-side phase, drug & LoA

$4.92

+0.2 (+4.2%)

C 59Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.65 B
EPS
-0.43
P/E Ratio
-
Value Trade
15.13 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    83.23 M

  • R&D Expenses

    35.05 M

  • Operating CF

    5.07 M

  • Total Assets

    610.24 M

  • Total Liabilities

    290.68 M

  • Equity

    319.56 M

  • D/E Ratio

    12,345

2.39 %
Week
-10.27 %
1 Month
-12.92 %
3 Month
-31.99 %
6 Month
-65.01 %
5 Year
-52.8 %
All Time
Cash Data
Profitable

  • Cash Position

    533.73 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 4, 2026
Overview
Volume
5.25 M
52 Week Range
1.57 - 9.75
% held by Insiders
27.36 %
% held by Institutions
53.58 %
Enterprise Value
1.33 B
Total Shares
342.59 M
Short %
22.71 %
Float Shares
236.38 M
Company Description
HQ: 1500 BROADWAY, NEW YORK, NY, 1...
Employees:307
https://www.nuvationbio.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
taletrectinib (IBTROZI) resected early-stage ROS1+ non-small cell lung cancer (NSCLC)
Phase 3
—
Small Molecules
Oncology
taletrectinib (IBTROZI) resected early-stage ROS1+ non-small cell lung cancer (NSCLC)
Phase 3
—
Small Molecules
Oncology
taletrectinib (IBTROZI) resected early-stage ROS1+ non-small cell lung cancer (NSCLC)
Phase 3
—
Small Molecules
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C59
Pipeline Score
$3.0B
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
1.8x
rNPV / MCap
Top 85%
Micro Cap
(rank 137 of 905)
Percentile Rank
Nuvation Bio Inc. carries a moderate pipeline score (59/100), with $7.5B risk-adjusted pipeline value, led by NUV-1511 in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
NUV-1511
Small molecule		Advanced Solid TumorPhase 1NCT0633443210% $3.3B ACTIVE NOT_RECRUITING 466 VERY_FAST C (43) Oct 1, 2027ELEVATED_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
taletrectinib (IBTROZI)
ROS1-positive non-small cell lung cancer (NSCLC)
Phase 2
2025-06-24
taletrectinib (IBTROZI)
ROS1-positive non-small cell lung cancer (NSCLC)
Phase 2
2025-06-24
taletrectinib (IBTROZI)
ROS1-positive non-small cell lung cancer (NSCLC)
Phase 2
2025-06-24
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in NUVB
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NUVB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NUVB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NUVB
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
NUVB Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
NUVB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Nuvation Bio Inc. (NUVB) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How NUVB ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Brain Tumors #4 of 45 PHASE 3 safusidenib
NVCR JAZZ DAWN
$3.55B 0.82 CONTENDER
Non-Small Cell Lung Cancer #16 of 88 PHASE 3 Taletrectinib + Crizotinib
MRK AMGN AZN
$28.1B 0.75 CONTENDER
Prostate Cancer #35 of 53 PHASE 1 NUV-1511
MRK AZN PFE
$25.12B 0.66 FOLLOWER
Pancreatic Cancer #41 of 73 PHASE 1 NUV-1511
RVMD RCUS AZN
$3.7B 0.66 FOLLOWER
Ovarian Cancer #41 of 61 PHASE 1 NUV-1511
MRK AZN LLY
$4.0B 0.66 FOLLOWER
Breast Cancer #48 of 94 PHASE 1 NUV-1511
MRK AZN GILD
$10.85B 0.66 FOLLOWER